About
Professor Andreas Suhrbier leads the Inflammation Biology Group. He did his undergraduate at Oxford University, UK (1978-82), PhD at Southampton Uni., UK (1982-5), his first post doc at Imperial College of Science and Technology, London (1986-1989) and came to Australia in 1990 on Royal Society and Wellcome Trust Fellowships.
Since 2004 he has held NHMRC fellowships, currently an Investigator Grant (Impact option: 100% Economic). He is an Honorary Professor at the University of Queensland and was the founding co-director of the Global Virus Network Center of Excellence at the AIDRC.
Professor Suhrbier has authored >200 publications with (>13,000 citations, and is an inventor on 19 patents; 13 commercialised, 11 led to human clinical trials, one covers ISCOM vaccines, five support Picato (http://bit.ly/39mUWhK). His research is focused on emerging viral diseases, and mouse models to understand disease and evaluate new interventions. The work utilises PC3/BSL3 facilities, with SARS-CoV-2 PC3 suite recently established.
During his career, he has been a consultant for Sementis, Valneva, Abivax, Leo Pharma, GSK, Paradigm, WHO, Aventis Pasteur, CSL, Bavarian Nordic, Peplin, C-Bio and Biocifer.
Research Skills
Mouse models, arboviruses, SARS-CoV-2, RNA-Seq, inflammation, vaccines.
Area of Interest
Emerging pathological viruses, inflammation, immunopathology, interventions, industry research and development.